[HPV (Human Papilloma Virus) implication in other cancers than gynaecological].

Autor: Badoual C; Service d'anatomie pathologique, faculté Paris-Descartes, hôpital européen Georges-Pompidou, AP-HP, 20-40, rue Leblanc, 75015 Paris, France; Inserm U 970, équipe 10, PARCC, 75015 Paris, France. Electronic address: cecile.badoual@egp.aphp.fr., Tartour E; Inserm U 970, équipe 10, PARCC, 75015 Paris, France; Laboratoire d'immunologie clinique, faculté Paris-Descartes, hôpital européen Georges-Pompidou, AP-HP, 20-40, rue Leblanc, 75015 Paris, France., Roussel H; Service d'anatomie pathologique, faculté Paris-Descartes, hôpital européen Georges-Pompidou, AP-HP, 20-40, rue Leblanc, 75015 Paris, France; Inserm U 970, équipe 10, PARCC, 75015 Paris, France., Bats AS; Service de gynécologie, faculté Paris-Descartes, hôpital européen Georges-Pompidou, AP-HP, 20-40, rue Leblanc, 75015 Paris, France., Pavie J; Service d'immunologie clinique, faculté Paris-Descartes, hôpital européen Georges-Pompidou, AP-HP, 20-40, rue Leblanc, 75015 Paris, France., Pernot S; Service de hépato-gastro-entérologie et oncologie digestive, faculté Paris-Descartes, hôpital européen Georges-Pompidou, AP-HP, 20-40, rue Leblanc, 75015 Paris, France., Weiss L; Service d'immunologie clinique, faculté Paris-Descartes, hôpital européen Georges-Pompidou, AP-HP, 20-40, rue Leblanc, 75015 Paris, France., Mohamed AS; Laboratoire de virologie, faculté Paris-Descartes, hôpital européen Georges-Pompidou, AP-HP, 20-40, rue Leblanc, 75015 Paris, France., Thariat J; Service de radiothérapie, centre Antoine Lacassagne, 227, avenue de la Lanterne, 06200 Nice, France., Hoffmann C; Service d'ORL, hôpital européen Georges-Pompidou, 20-40, rue Leblanc, 75015 Paris, France., Péré H; Laboratoire de virologie, faculté Paris-Descartes, hôpital européen Georges-Pompidou, AP-HP, 20-40, rue Leblanc, 75015 Paris, France; Inserm U 970, équipe 10, PARCC, 75015 Paris, France.
Jazyk: francouzština
Zdroj: La Revue de medecine interne [Rev Med Interne] 2015 Aug; Vol. 36 (8), pp. 540-7. Date of Electronic Publication: 2015 Feb 07.
DOI: 10.1016/j.revmed.2015.01.003
Abstrakt: Worldwide, approximately 5 to 10% of the population is infected by a Human Papilloma Virus (HPV). Some of these viruses, with a high oncogenic risk (HPV HR), are responsible for about 5% of cancer. It is now accepted that almost all carcinomas of the cervix and the vulva are due to an HPV HR (HPV16 and 18) infection. However, these viruses are known to be involved in the carcinogenesis of many other cancers (head and neck [SCCHN], penis, anus). For head and neck cancer, HPV infection is considered as a good prognostic factor. The role of HPV HR in anal cancer is also extensively studied in high-risk patient's population. The role of HPV infection in the carcinogenesis of esophageal, bladder, lung, breast or skin cancers is still debated. Given the multiple possible locations of HPV HR infection, the question of optimizing the management of patients with a HPV+ cancer arises in the implementation of a comprehensive clinical and biological monitoring. It is the same in therapeutics with the existence of a preventive vaccination, for example.
(Copyright © 2015 Société nationale française de médecine interne (SNFMI). Published by Elsevier SAS. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: